Login to Your Account

Financings Roundup

Dynavax Pads Coffers Again; $74M to Back Heplisav Launch

By Trista Morrison
Staff Writer

Thursday, May 10, 2012
Six months after raising $69 million to support the anticipated launch of hepatitis B vaccine Heplisav, Dynavax Technologies Corp. is at it again. The Berkeley, Calif.-based biotech completed another public offering, this time raising $74.4 million for more Heplisav ramp-up.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription